Estradiol and progesterone regulate the proliferation of human breast epithelial cells.

Authors: Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Publication Year: 1998 Citation: Fertil Steril 1998;69(5):963-9. In this double-blind randomized study to evaluate the effects of estrogen and progesterone on normal breast cells, 40 postmenopausal women received daily topical application of a gel containing either placebo, estradiol, progesterone, …

Progesterone receptor activation – an alternative to SERMs in breast cancer.

Authors: Desreux J, Kebers F, Noel A, Francart D, Van Cauwenberge H, Heinen V, Thomas JL, Bernard AM, Paris J, Delansorne R, Foidart JM. Publication Year: 2000 Citation: Eur J Cancer 2000;36 Suppl 4:S90-1. This review emphasizes progesterone‚Äôs role in supporting healthy breast homeostasis and opposing the proliferative effects of estradiol in the breast, unlike …

Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture.

Authors: Malet C, Spritzer P, Guillaumin D, Kuttenn F. Publication Year: 2000 Citation: J Steroid Biochem Mol Biol 2000; 73: 171-81. In a culture system, progesterone was found to have an inhibitory effect on breast cell growth. When given following estradiol (E2), it limited the stimulatory effect of E2 on cell growth. http://www.ncbi.nlm.nih.gov/pubmed/10925217

Pregnancy, progesterone and progestins in relation to breast cancer risk.

Authors: Campagnoli C, Abba C, Ambroggio S, Peris C. Publication Year: 2005 Citation: J Steroid Biochem Mol Biol 2005; 97(5):441-50. The authors review recent findings that show that the production of progesterone during pregnancy and the use of bioidentical progesterone in hormone therapy do not increase breast cancer risk, and can even protect against the …

Osteoporosis reversal; the role of progesterone.

Author: Lee JR. Publication Year: 1990 Citation: International Clinical Nutrition Review 1990;10(3):384-91. Transdermal progesterone supplementation with and without conjugated estrogens was evaluated in a clinical setting using 100 women aged 38 to 83 years. The average time from onset of menopause was 16 years. 63 women were followed for three years with dual photon absorptiometry. …